Mereo Financial Statements From 2010 to 2025

MREO Stock  USD 2.93  0.06  2.09%   
Mereo BioPharma financial statements provide useful quarterly and yearly information to potential Mereo BioPharma Group investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Mereo BioPharma financial statements helps investors assess Mereo BioPharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Mereo BioPharma's valuation are summarized below:
Gross Profit
936 K
Market Capitalization
630.8 M
Enterprise Value Revenue
380.7356
Revenue
1000 K
Earnings Share
(0.25)
We have found one hundred twenty available fundamental ratios for Mereo BioPharma, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Mereo BioPharma's last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 30th of January 2025, Market Cap is likely to grow to about 1.4 B. Also, Enterprise Value is likely to grow to about 1.4 B

Mereo BioPharma Total Revenue

12.07 Million

Check Mereo BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mereo BioPharma's main balance sheet or income statement drivers, such as Interest Income of 2.6 M, Discontinued Operations of 0.0 or Interest Expense of 2.9 M, as well as many indicators such as Price To Sales Ratio of 137, Dividend Yield of 0.0 or PTB Ratio of 28.49. Mereo financial statements analysis is a perfect complement when working with Mereo BioPharma Valuation or Volatility modules.
  
Check out the analysis of Mereo BioPharma Correlation against competitors.

Mereo BioPharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets70.1 M59.8 M90.9 M
Slightly volatile
Short and Long Term Debt Total6.5 M6.8 M10.1 M
Slightly volatile
Other Current Liabilities5.4 M6.7 M3.7 M
Slightly volatile
Total Current Liabilities14.3 M10.9 M9.8 M
Slightly volatile
Other Liabilities339.8 K357.6 K4.7 M
Pretty Stable
Property Plant And Equipment Net2.4 M1.9 M1.6 M
Slightly volatile
Accounts Payable2.8 M2.1 M3.1 M
Very volatile
Cash55.8 M66 M61 M
Slightly volatile
Non Current Assets Total2.3 M2.5 M24.9 M
Slightly volatile
Cash And Short Term Investments41 M51.7 M59.5 M
Slightly volatile
Net Receivables3.8 M3.4 M3.5 M
Pretty Stable
Common Stock Total Equity1.2 M1.2 M483.4 K
Slightly volatile
Liabilities And Stockholders Equity70.1 M59.8 M90.9 M
Slightly volatile
Non Current Liabilities Total7.1 M7.4 M12.4 M
Pretty Stable
Capital Surpluse106.6 M139.9 M84.3 M
Slightly volatile
Other Current Assets2.2 M2.3 M5.9 M
Very volatile
Other Stockholder Equity585.5 M557.6 M246.9 M
Slightly volatile
Total Liabilities35 M18.4 M23 M
Slightly volatile
Property Plant And Equipment Gross3.1 M2.8 MM
Slightly volatile
Total Current Assets64.2 M73.3 M66.8 M
Slightly volatile
Intangible Assets931.1 K980.1 K23.4 M
Slightly volatile
Common Stock3.4 M3.2 M952.1 K
Slightly volatile
Property Plant Equipment2.5 M2.1 M1.6 M
Slightly volatile
Net Invested Capital49.1 M49.4 M69.4 M
Slightly volatile
Net Working Capital42.8 M62.4 M47 M
Pretty Stable
Capital Stock3.4 M3.2 MM
Slightly volatile

Mereo BioPharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income2.6 M2.5 M606.4 K
Slightly volatile
Selling General Administrative16.3 M21.2 M13.1 M
Slightly volatile
Total Operating Expenses63.1 M32.3 M212.3 M
Slightly volatile
Depreciation And Amortization761.7 K1.2 M482.4 K
Slightly volatile
Reconciled Depreciation892.6 K1.2 M502.8 K
Slightly volatile

Mereo BioPharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation699.6 K1.2 M481.3 K
Slightly volatile
Capital Expenditures315.7 K377.1 K332.7 K
Very volatile
End Period Cash Flow47.5 M66 M35.2 M
Slightly volatile
Stock Based Compensation4.2 M5.7 M4.9 M
Slightly volatile
Begin Period Cash Flow47.2 M78.4 M33.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Days Sales Outstanding149157719
Slightly volatile
Average Payables3.5 MM4.3 M
Slightly volatile
Capex To Depreciation0.430.454.2159
Very volatile
Payables Turnover1.21.2611.1563
Slightly volatile
Cash Per Share0.09510.10.6503
Slightly volatile
Days Payables Outstanding203299165
Slightly volatile
Intangibles To Total Assets0.01790.01880.2567
Slightly volatile
Current Ratio9.557.7314.9784
Slightly volatile
Receivables Turnover2.933.082.4494
Slightly volatile
Graham Number0.30.322.8076
Slightly volatile
Capex Per Share7.0E-47.0E-40.0023
Very volatile
Interest Debt Per Share0.01460.01540.1092
Pretty Stable
Debt To Assets0.140.08060.1234
Slightly volatile
Days Of Payables Outstanding203299165
Slightly volatile
Effective Tax Rate0.01940.02040.113
Slightly volatile
Long Term Debt To Capitalization0.06840.0720.9408
Pretty Stable
Total Debt To Capitalization0.09010.09480.4976
Pretty Stable
Quick Ratio11.787.7316.26
Slightly volatile
Net Income Per E B T0.720.880.8645
Pretty Stable
Cash Ratio8.666.9614.2434
Slightly volatile
Days Of Sales Outstanding149157719
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.920.9961
Slightly volatile
Debt Ratio0.140.08060.1234
Slightly volatile

Mereo BioPharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 B1.4 B605.9 M
Slightly volatile
Enterprise Value1.4 B1.3 B567.8 M
Slightly volatile

Mereo Fundamental Market Drivers

Cash And Short Term Investments57.4 M

Mereo Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Mereo BioPharma Financial Statements

Mereo BioPharma investors utilize fundamental indicators, such as revenue or net income, to predict how Mereo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue7.4 M4.4 M
Total Revenue11.5 M12.1 M
Cost Of Revenue2.3 M2.2 M
Stock Based Compensation To Revenue 0.44  0.47 
Sales General And Administrative To Revenue 1.66  1.74 
Research And Ddevelopement To Revenue 2.00  1.90 
Capex To Revenue 0.04  0.04 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(3.27)(3.10)

Pair Trading with Mereo BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Mereo Stock

  0.54BMY Bristol Myers Squibb Earnings Call This WeekPairCorr
  0.52MLAB Mesa Laboratories Earnings Call This WeekPairCorr
  0.32GILD Gilead Sciences Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:
Check out the analysis of Mereo BioPharma Correlation against competitors.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.25)
Revenue Per Share
0.007
Return On Assets
(0.24)
Return On Equity
(0.48)
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.